| Phenotype / cell stem origin | The cell of origin is a peripheral CD4+ T-lymphocyte. The immunophenotype of the neoplastic clone is CD3+ CD5+ CD4+ CD25-. Rare CD8+/CD4- cases were observed. Clonality studies demonstrated a monoclonal rearrangement of the T-cell receptor (TCR). |
| Epidemiology | This is the most common form of cutaneous T-cell lymphoma. The annual incidence is around 0,3 cases per 100.000 in western countries. The median age at diagnosis is between 55 and 60 years, with a 2/1 male-to-female ratio. |
| Clinics | The disease usually shows cutaneous patches, plaques, tumors or generalized erythroderma (Mycosis fungoides). Pruritus is a common symptom. Extracutaneous manifestations are more frequent in the presence of locally advanced disease (cutaneous tumors). The presence of erythroderma with circulating malignant cells (Sezary's cells) in the peripheral blood (PB) and in the bone marrow is consistent with Sezary's syndrome, which is usually associated with lymphadenopathy. Other sites of involvement in disseminated disease include the lungs, the gastrointestinal tract, the liver and the central nervous system. |
| Pathology | The tumor cell is a small lymphocyte with cerebriform nucleus, clumped chromatin and inconspicuous nucleoli. Epidermotropism by neoplastic CD4+ lymphocytes with the formation of Pautrier's microabsecsses is the hallmark of the disease. |
| Treatment | Phototherapy, radiation therapy and alpha interferon are the mainstay of treatment of cutaneous disease. Chemotherapy using various regimens was employed in cases displaying disseminated disease and in Sezary's syndrome with limited success. |
| Prognosis | The clinical stage is the most important indicator. Patient with limited cutaneous disease have an excellent prognosis. Patient with cutaneous tumours, generalized erythroderma, with Sezary's syndrome or extracutaneous disease usually have a short survival, ranging from 1 to 4 years. |
| Cutaneous T-cell lymphomas |
| Kim Y, Hoppe RT |
| In. : page M. |
| |
| Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sˆ©zary syndrome. |
| Thangavelu M, Finn WG, Yelavarthi KK, Roenigk HH Jr, Samuelson E, Peterson L, Kuzel TM, Rosen ST |
| Blood. 1997 ; 89 (9) : 3371-3377. |
| PMID 9129044 |
| |
| Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sˆ©zary syndrome and mycosis fungoides. |
| Mao X, Lillington D, Scarisbrick JJ, Mitchell T, Czepulkowski B, Russell-Jones R, Young B, Whittaker SJ |
| The British journal of dermatology. 2002 ; 147 (3) : 464-475. |
| PMID 12207585 |
| |
| Molecular cytogenetic detection of chromosomal breakpoints in T-cell receptor gene loci. |
| Gesk S, Martˆ‚n-Subero JI, Harder L, Luhmann B, Schlegelberger B, Calasanz MJ, Grote W, Siebert R |
| Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003 ; 17 (4) : 738-745. |
| PMID 12682631 |
| |
| Molecular cytogenetic characterization of Sˆ©zary syndrome. |
| Mao X, Lillington DM, Czepulkowski B, Russell-Jones R, Young BD, Whittaker S |
| Genes, chromosomes & cancer. 2003 ; 36 (3) : 250-260. |
| PMID 12557225 |
| |
| Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. |
| Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ |
| Blood. 2003 ; 101 (4) : 1513-1519. |
| PMID 12393503 |
| |